ArticleJournal of animal science and biotechnology2025
Docosahexaenoic acid (DHA) alleviates hepatic lipid deposition in dairy cows during the transition period: an integrated in vitro and in vivo study.
Article in Journal of animal science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial Communication with Cellular Organelles in the Pathogenesis of Fatty Liver Disease in Domestic and Model Animals.Animals : an open access journal from MDPI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFatty liver syndrome is a prevalent metabolic disorder in transition dairy cows, characterized by excessive hepatic lipid accumulation that impairs liver function and leads to systemic metabolic disturbances. Docosahexaenoic acid (DHA), a prominent n-3 polyunsaturated fatty acid (PUFA), not only exhibits anti-inflammatory and anti-oxidative properties, but also holds potential in ameliorating lipid metabolism. This study integrated in vitro bovine primary hepatocyte models and in vivo dairy cow trials to investigate the regulatory effects of DHA on hepatic lipid deposition.
resultsIn vitro, 40 μmol/L DHA significantly reduced triglyceride (TAG) accumulation in steatotic hepatocytes by downregulating genes involved in fatty acid transport (FABP-1, CD36) and lipogenesis (DGAT2, FAS, SREBP-1C), while upregulating markers of lipolysis (CGI-58, ATGL) and fatty acid oxidation (ACADL, CPT1A, CPT2). Transmission electron microscopy (TEM) confirmed DHA-mediated restoration of mitochondrial ultrastructure and enhanced lipid droplet (LD)-mitochondria interactions. In vivo, dietary rumen-protected DHA (180 g/d) supplementation reduced hepatic lipid deposition, improved liver function (evidenced by decreased total bilirubin and alanine aminotransferase), reduced oxidative stress and inflammation (suppressed malondialdehyde, glutathione peroxidase, and lipopolysaccharide), coincided with relieving insulin resistance (reduced insulin and glucose, as well increased adiponectin) in dairy cows with fatty liver. These improvements may be attributed to increased expression of TOMM20 and MtCo-1, promoting mitochondrial biogenesis and β-oxidation, along with an elevated plasma n-3/n-6 ratio.
conclusionsCollectively, these findings suggest that DHA supplementation represents a promising nutritional strategy for preventing spontaneous fatty liver in transition dairy cows by enhancing hepatic lipid clearance and restoring metabolic homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.